Axsome Therapeutics Financials
AXSM Stock | USD 99.65 2.62 2.70% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 5.83 | 3.6316 |
|
|
Investors should never underestimate Axsome Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Axsome Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Axsome Therapeutics.
Net Income |
|
Axsome | Select Account or Indicator |
Understanding current and past Axsome Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Axsome Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Axsome Therapeutics' assets may result in an increase in income on the income statement.
Axsome Therapeutics Earnings Geography
Axsome Therapeutics Stock Summary
Axsome Therapeutics competes with Incyte, Sarepta Therapeutics, ACADIA Pharmaceuticals, Viking Therapeutics, and Madrigal Pharmaceuticals. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 198 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US05464T1043 |
CUSIP | 05464T104 |
Location | New York; U.S.A |
Business Address | One World Trade |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.axsome.com |
Phone | 212 332 3241 |
Currency | USD - US Dollar |
Axsome Therapeutics Key Financial Ratios
Return On Equity | -1.72 | ||||
Profit Margin | (0.92) % | ||||
Operating Margin | (0.44) % | ||||
Price To Sales | 14.27 X | ||||
Revenue | 270.6 M |
Axsome Therapeutics Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 220.5M | 186.1M | (338.4M) | 331.5M | 588.2M | 617.6M | |
Other Current Liab | 683.2K | 8.7M | 9.3M | 57.5M | 95.6M | 100.4M | |
Net Debt | (200.0M) | (133.8M) | (36.8M) | (106.2M) | (199.8M) | (189.8M) | |
Retained Earnings | (175.9M) | (278.8M) | (409.2M) | (596.3M) | (835.6M) | (793.8M) | |
Accounts Payable | 10.9M | 13.5M | 13.1M | 38.6M | 40.7M | 42.7M | |
Cash | 220.0M | 183.9M | 86.5M | 200.8M | 386.2M | 405.5M | |
Other Current Assets | 413.1K | 148.4K | 45.3K | 5.6M | 8.1M | 8.5M | |
Total Liab | 41.8M | 72.3M | 70.8M | 221.9M | 397.3M | 417.1M | |
Total Current Assets | 220.4M | 184.0M | 86.5M | 245.6M | 504.3M | 529.5M | |
Short Term Debt | 2.6M | 1.2M | 620.7K | 425K | 2.5M | 1.4M | |
Common Stock | 3.7K | 3.7K | 3.8K | 4.4K | 5K | 3.2K | |
Net Tangible Assets | 178.7M | 113.8M | 15.6M | 39.6M | 45.5M | 52.6M | |
Other Assets | 139.9K | 2.1M | (426.1M) | 14.7M | 13.2M | 13.9M | |
Long Term Debt | 17.3M | 48.3M | 49.1M | 94.3M | 178.1M | 187.0M | |
Long Term Debt Total | 3.6M | 17.3M | 48.3M | 49.1M | 56.5M | 59.3M | |
Capital Surpluse | 108.5M | 354.6M | 392.6M | 424.8M | 488.5M | 264.6M | |
Net Invested Capital | 198.7M | 162.1M | 64.7M | 203.8M | 369.0M | 387.5M | |
Net Working Capital | 195.9M | 160.6M | 63.5M | 149.1M | 365.4M | 383.7M | |
Capital Stock | 3.7K | 3.7K | 3.8K | 4.4K | 5K | 4.3K |
Axsome Therapeutics Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 1.2M | 2.6M | 5.7M | 7.3M | 6.5M | 6.8M | |
Operating Income | (67.2M) | (99.1M) | (124.7M) | (176.5M) | (231.8M) | (220.2M) | |
Ebit | (67.1M) | (99.1M) | (124.7M) | (179.8M) | (231.8M) | (220.2M) | |
Research Development | 53.6M | 70.2M | 58.1M | 57.9M | 97.9M | 102.8M | |
Ebitda | (67.1M) | (99.1M) | (123.6M) | (174.2M) | (225.0M) | (213.7M) | |
Income Before Tax | (68.3M) | (102.9M) | (130.4M) | (187.1M) | (238.3M) | (226.4M) | |
Net Income | (69.7M) | (105.4M) | (134.9M) | (197.8M) | (239.2M) | (227.3M) | |
Income Tax Expense | 1.3M | 2.5M | 4.5M | 10.6M | 960K | 912K | |
Gross Profit | (37.3K) | (77.7K) | (1.2M) | 44.8M | 244.5M | 256.8M | |
Cost Of Revenue | 37.3K | 77.7K | 1.2M | 5.2M | 26.1M | 27.4M | |
Net Interest Income | (1.2M) | (2.6M) | (5.7M) | (7.3M) | (6.5M) | (6.1M) |
Axsome Therapeutics Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 206.0M | (36.1M) | (97.4M) | 114.4M | 185.4M | 194.6M | |
Free Cash Flow | (46.4M) | (78.5M) | (108.5M) | (117.2M) | (145.7M) | (138.4M) | |
Other Non Cash Items | 650.0K | 8.0M | (104.6K) | 3.7M | 53.1M | 55.8M | |
Capital Expenditures | 16.1K | 45.9K | 307.5K | 702.1K | 582K | 611.1K | |
Net Income | (68.3M) | (102.9M) | (130.4M) | (187.1M) | (239.2M) | (227.3M) | |
End Period Cash Flow | 220.0M | 183.9M | 86.5M | 200.8M | 386.2M | 405.5M | |
Net Borrowings | 12.8M | 27.2M | (309.3K) | 45M | 51.8M | 54.3M | |
Depreciation | 37.3K | 77.7K | 1.2M | 5.6M | 6.8M | 7.2M | |
Change To Netincome | 6.1M | 16.0M | 20.8M | 39.9M | 45.9M | 48.2M | |
Investments | (16.1K) | (45.9K) | (307.5K) | (53.7M) | (582K) | (611.1K) |
Axsome Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Axsome Therapeutics's current stock value. Our valuation model uses many indicators to compare Axsome Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Axsome Therapeutics competition to find correlations between indicators driving Axsome Therapeutics's intrinsic value. More Info.Axsome Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Axsome Therapeutics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Axsome Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Axsome Therapeutics Systematic Risk
Axsome Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Axsome Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Axsome Therapeutics correlated with the market. If Beta is less than 0 Axsome Therapeutics generally moves in the opposite direction as compared to the market. If Axsome Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Axsome Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Axsome Therapeutics is generally in the same direction as the market. If Beta > 1 Axsome Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Axsome Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Axsome Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Axsome Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Axsome Therapeutics November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Axsome Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Axsome Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Axsome Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Axsome Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Axsome Therapeutics's daily price indicators and compare them against related drivers.
Downside Deviation | 1.99 | |||
Information Ratio | 0.0311 | |||
Maximum Drawdown | 13.67 | |||
Value At Risk | (3.78) | |||
Potential Upside | 4.1 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.58) | Revenue Per Share 7.108 | Quarterly Revenue Growth 0.813 | Return On Assets (0.26) | Return On Equity (1.72) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.